Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

News Conference News VIVA 2020

BVS Reboot? Signs of Durability to 2 Years in Critical Limb-Threatening Ischemia

L.A. McKeown

November 11, 2020

News Conference News TCT 2020

EXAMINATION Surprise: Few Late Event Gaps Between DES and BMS in STEMI

L.A. McKeown

October 22, 2020

News Conference News TCT 2020

OPTIMIZE: Svelte Direct Stenting Device Fails to Match DES

L.A. McKeown

October 17, 2020

Presentation TCT 2020

TCT ID 7: Everolimus-Eluting Stent vs Bare-Metal Stent in ST-Segment Elevation Myocardial Infarction – 10-Year Follow-up of the Multicentre Randomized Controlled Examination Trial

Presenter: Salvatore Brugaletta

October 15, 2020

Presentation TCT 2020

TCT 262: Percutaneous Coronary Intervention of Long Coronary Lesions With the Bioabsorbable Polymer-Coated, Everolimus-Eluting SYNERGY 48 mm Stent: Primary Outcomes of the EVOLVE 48 Study

Presenter: Dimitri Karmpaliotis

October 14, 2020

Presentation TCT 2020

TCT 269: A First-in-Human Study of the Second-Generation, Thin-Strut, Everolimus-Eluting Bioresorbable Scaffold: Final IVUS and OCT Results From the FAST Clinical Trial

Presenter: Takeshi Nishi

October 14, 2020

Presentation TCT 2020

TCT 276: A 'Real-World' Multi-center Registry Evaluating Safety and Clinical Performance of Biodegradable Polymer-coated Ultra-thin Everolimus-eluting Stents: 3-year Results from the PERFORM-EVER Registry

Presenter: Sridhar Kasturi, MD

October 14, 2020

In-Stent Restenosis Accounts for 10% of All PCIs, Contemporary National Analysis Shows

News Daily News

In-Stent Restenosis Accounts for 10% of All PCIs, National Analysis Shows

L.A. McKeown

September 24, 2020

News Daily News

‘Aspirin-Free’ Antiplatelet Strategy Feasible After PCI, Pilot Study Suggests

Michael O'Riordan

September 18, 2020

Podcast TCTMD Talking Points

EVOLVE Short DAPT: 3-Month DAPT in Patients at High Bleeding Risk Treated with a Bioabsorbable Polymer-Based Everolimus-Eluting Stent

July 22, 2020

News Daily News

In CAD, No Long-term Safety Signal for Paclitaxel DCBs: Meta-analysis

L.A. McKeown

March 09, 2020

News Conference News CRT 2020

Newer, Thinner-Strut Abbott Scaffold Prompts Talk of a BVS Comeback

Michael O'Riordan

February 28, 2020

News Conference News CRT 2020

BIOFLOW V: Orsiro Bests Xience at 3 Years for TLF, Late Stent Thrombosis

L.A. McKeown

February 25, 2020

News Daily News

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

Michael O'Riordan

February 10, 2020

News Daily News

Revascularization After PCI or CABG Linked to Higher Mortality: EXCEL

Michael O'Riordan

January 17, 2020

News Daily News

EACTS Offers to Help to Resolve EXCEL Controversy, as CRF Launches Review

Michael O'Riordan

January 08, 2020

Video

» Interview

Assessment of Three-Month and One-Month DAPT After Everolimus-Eluting Stents in High-Bleeding Risk Patients

October 15, 2020

Advertisement

BVS Reboot? Signs of Durability to 2 Years in Critical Limb-Threatening Ischemia

EXAMINATION Surprise: Few Late Event Gaps Between DES and BMS in STEMI

OPTIMIZE: Svelte Direct Stenting Device Fails to Match DES

TCT ID 7: Everolimus-Eluting Stent vs Bare-Metal Stent in ST-Segment Elevation Myocardial Infarction – 10-Year Follow-up of the Multicentre Randomized Controlled Examination Trial

TCT 262: Percutaneous Coronary Intervention of Long Coronary Lesions With the Bioabsorbable Polymer-Coated, Everolimus-Eluting SYNERGY 48 mm Stent: Primary Outcomes of the EVOLVE 48 Study

TCT 269: A First-in-Human Study of the Second-Generation, Thin-Strut, Everolimus-Eluting Bioresorbable Scaffold: Final IVUS and OCT Results From the FAST Clinical Trial

TCT 276: A 'Real-World' Multi-center Registry Evaluating Safety and Clinical Performance of Biodegradable Polymer-coated Ultra-thin Everolimus-eluting Stents: 3-year Results from the PERFORM-EVER Registry

In-Stent Restenosis Accounts for 10% of All PCIs, National Analysis Shows

‘Aspirin-Free’ Antiplatelet Strategy Feasible After PCI, Pilot Study Suggests

EVOLVE Short DAPT: 3-Month DAPT in Patients at High Bleeding Risk Treated with a Bioabsorbable Polymer-Based Everolimus-Eluting Stent

In CAD, No Long-term Safety Signal for Paclitaxel DCBs: Meta-analysis

Newer, Thinner-Strut Abbott Scaffold Prompts Talk of a BVS Comeback

BIOFLOW V: Orsiro Bests Xience at 3 Years for TLF, Late Stent Thrombosis

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

Revascularization After PCI or CABG Linked to Higher Mortality: EXCEL

EACTS Offers to Help to Resolve EXCEL Controversy, as CRF Launches Review

Assessment of Three-Month and One-Month DAPT After Everolimus-Eluting Stents in High-Bleeding Risk Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content